Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8809985 | 0.98 | KDM4E (0.49) | KDM4EALDH1A1HSD17B10 | |
| Isopropylamine SCHEMBL9565383 | 0.93 | KDM4E (0.44) | KDM4EALDH1A1HSD17B10 | |
| SCHEMBL8809973 | 0.85 | KDM4E (0.37) | KDM4EALDH1A1HSD17B10 | |
| Isopropylamine SCHEMBL8953470 | 0.85 | KDM4E (0.40) | KDM4EALDH1A1HSD17B10 | |
| SCHEMBL2284904 | 0.84 | ALDH1A1 (0.38) | KDM4EALDH1A1HSD17B10 | |
| SCHEMBL8812499 | 0.82 | NPSR1 (0.44) | — | |
| Ammonia Solution, Strong SCHEMBL9570533 | 0.81 | CA12 (0.38) | KDM4EALDH1A1HSD17B10 | |
| SCHEMBL2290901 | 0.79 | CHRM4 (0.36) | KDM4EALDH1A1HSD17B10 | |
| SCHEMBL2288979 | 0.76 | CYP1A2 (0.38) | ALDH1A1HSD17B10 | |
| SCHEMBL10181023 | 0.76 | CYP1A2 (0.53) | KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0461079-B1 | Substituted phthalides and heterocyclic phthalides | CIBA GEIGY AG (CH) | 1997-07-16 | — | — | EP | claimed |
| US-20140234225-A1 | METHOD OF TREATMENT USING NANOPARTICULATE COMPOSITIONS HAVING LYSOZYME AS A SURFACE STABILIZER | ALKERMES PHARMA IRELAND LIMITED (IE) | 2014-08-21 | — | — | US | disclosed |
| US-8652464-B2 | Method of treatment using nanoparticulate compositions having lysozyme as a surface stabilizer | ALKERMES PHARMA IRELAND LIMITED (IE) | 2014-02-18 | — | — | US | disclosed |
| US-20130224123-A1 | NANOPARTICULATE COMPOSITIONS HAVING LYSOZYME AS A SURFACE STABILIZER | ALKERMES PHARMA IRELAND LIMITED (IE) | 2013-08-29 | — | — | US | disclosed |
| US-8323641-B2 | Nanoparticulate compositions having lysozyme as a surface stabilizer | ALKERMES PHARMA IRELAND LIMITED (IE) | 2012-12-04 | — | — | US | disclosed |
| EP-2272342-B1 | Herbicidal compositions | BASF SE (DE) | 2012-06-27 | — | — | EP | disclosed |
| EP-2050338-B1 | Herbicidal compositions | BASF SE (DE) | 2011-05-25 | — | — | EP | disclosed |
| EP-2272342-A2 | Herbicidal compositions | BASF SE (DE) | 2011-01-12 | — | — | EP | disclosed |
| EP-2272341-A2 | Herbizide Zusammensetzungen | BASF SE (DE) | 2011-01-12 | — | — | EP | disclosed |
| US-7850995-B2 | Bioadhesive nanoparticulate compositions having cationic surface stabilizers | ELAN PHARMA INTERNATIONAL, LTD. (IE) | 2010-12-14 | — | — | US | disclosed |
| US-5665674-A | SEMICARBAZONES | SANDOZ LTD. (CH) | 1997-09-09 | — | — | US | disclosed |
| US-5665673-A | SEMICARBAZONES | BASF AKTIENGESELLSCHAFT (DE) | 1997-09-09 | — | — | US | disclosed |
| US-5633437-A | ISOLATED NUCLEIC ACID SEQUENCE | SANDOZ LTD. (CH) | 1997-05-27 | — | — | US | disclosed |
| US-5627138-A | HERBICIDES | SANDOZ LTD. (CH) | 1997-05-06 | — | — | US | disclosed |
| US-5627137-A | HERBICIDES | SANDOZ LTD. (CH) | 1997-05-06 | — | — | US | disclosed |
| US-5561101-A | HERBICIDES | SANDOZ LTD. (CH) | 1996-10-01 | — | — | US | disclosed |
| US-5506192-A | HERBICIDES | SANDOZ LTD. | 1996-04-09 | — | — | US | disclosed |
| EP-0646315-A1 | Novel compositions containing an auxin transport inhibitor and another herbicide | SANDOZ LTD. (CH) | 1995-04-05 | — | — | EP | disclosed |
| EP-0614606-A2 | Herbicidal compositions | SANDOZ LTD. (CH) | 1994-09-14 | — | — | EP | disclosed |
| EP-0549524-A1 | Substituted phthalides and heterocyclic phthalides and their use in agriculture | SANDOZ LTD. (CH) | 1993-06-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140234225-A1 | METHOD OF TREATMENT USING NANOPARTICULATE COMPOSITIONS HAVING LYSOZYME AS A SURFACE STABILIZER | LPO, LCT, LIPA | KDM4E 2042/4885ALDH1A1 2578/4885HSD17B10 2494/4885 |
| US-20130224123-A1 | NANOPARTICULATE COMPOSITIONS HAVING LYSOZYME AS A SURFACE STABILIZER | LPO, LCT, CTSA | KDM4E 1781/4885ALDH1A1 2533/4885HSD17B10 3100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.